Drug delivery by an enzyme-mediated cyclization of a lipid prodrug with unique bilayer-formation properties

Angewandte Chemie - International Edition

Volumn 48, Issue 10, 2009, Pages 1823-1826

  Linderoth, Lars ^a   Peters, G̈nther H ^a,b   Madsen, Robert ^a   Andresen, Thomas L ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b MEMPHYS Center for Biomembrane Physics   (Denmark)

Author keywords

Cyclization; Drug delivery; Liposomes; Phospholipase; Prodrugs

Indexed keywords

DRUG DELIVERY; ENZYMES; LIPOSOMES; PHOSPHOLIPIDS; SUGAR (SUCROSE);

BI LAYERS; CYCLIZATION REACTIONS; DRUG-DELIVERY SYSTEMS; PHOSPHOLIPASE; PRODRUG; PRODRUGS; SMALL UNILAMELLAR VESICLES;

CYCLIZATION;

CAPSAICIN; LIPOSOME; PRODRUG; SECRETORY PHOSPHOLIPASE A2;

ARTICLE; CHEMISTRY; CYCLIZATION; DRUG DELIVERY SYSTEM; HUMAN; LIPID BILAYER; MASS SPECTROMETRY; METABOLISM; SYNTHESIS;

CAPSAICIN; CYCLIZATION; DRUG DELIVERY SYSTEMS; HUMANS; LIPID BILAYERS; LIPOSOMES; PHOSPHOLIPASES A2, SECRETORY; PRODRUGS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 61349180159     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200805241     Document Type: Article

References (24)

1. a) R. Langer, D. A. Tirell, Nature 2004, 428, 487 - 492;
2. b) T. M. Allen, P. R. Cullis, Science 2004, 303, 1818-1822;
3. c) D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer, Nat. Nanotechnol. 2007, 2, 751 -760.
4. a) T. L. Andresen, S. S. Jensen, K. J0rgensen, Prog. Lipid Res. 2005, 44, 68 - 97;
5. b) T. L. Andresen, J. Davidsen, M. Begtrup, O. G. Mouritsen, K. Jørgensen, J. Med. Chem. 2004, 47, 1694-1703.
6. a) Y. Barenholz, Curr. Opin. Colloid Interface Sci. 2001, 6,66-77;
7. b) G. Storm, D. J. A. Crommelin, Pharm. Sci. Technol. Today 1998, 1, 19-31;
8. c) V. P. Torchilin, N. A. Lukyanov, Z. Gao, B. Papahadjopoulos-Sternberg, Proc. Natl. Acad. Sci. USA 2003, 100, 6039-6044.
9. L. Yanga, P. Alexandridis, Curr. Opin. Colloid Interface Sci. 2000, 5, 132-143.
10. a) D. E. Discher, A. Eisenberg, Science 2002, 297, 967-973;
11. b) H. Lomas, I. Canton, S. MacNeil, D. Jianzhong, S. P. Armes, A. J. Ryan, A. L. Lewis, G. Battaglia, Adv. Mater. 2007, 19, 4238 -4243.
12. a) D. C. Drummond, M. Zignani, J. Leroux, Prog. Lipid Res. 2000, 39, 409-460;
13. b) D. Needham, M. W. Dewhirst, Adv. Drug Delivery Rev. 2001, 53, 285 -305.
14. D. L. Scott, S. P. White, Z. Otwinowski, W. Yuan, M. H. Gelb, P. B. Sigler, Science 1990, 250, 1541 -1546.
15. a) S. Yamashita, M. Ogawa, K. Sakamoto, T. Abe, H. Arakawa, J. Yamashita, Clin. Chim. Acta 1994, 228,91-99;
16. b)T.Abe,K. Sakamoto, H. Kamohara, Y. Hirano, N. Kuwahara, M. Ogawa, Int. J. Cancer 1997, 74, 245 -250.
17. a) L. Linderoth, T. L. Andresen, K. J0rgensen, R. Madsen, G. H. Peters, Biophys. J. 2008, 94, 14 - 27;
18. b) G. H. Peters, M. S. Møller, K. Jørgensen, P. Rönnholm, M. Mikkelsen, T. L. Andresen, J. Am. Chem. Soc. 2007, 129, 5451 -5461.
19. a) Y.-J. Surh, E. Lee, J. M. Lee, Mutat. Res. 1998, 402, 259 - 267;
20. b) M. Y. Jung, H. J. Kang, A. Moon, Cancer Lett. 2001, 65, 139-145.
21. S. L. Beaucage, R. P. Iyer, Tetrahedron 1993, 49, 10441 -10488.
22. T. L. Andresen, D. M. Skytte, R. Madsen, Org. Biomol. Chem. 2004, 2, 2951-2957.
23. a) C. Leidy, L. Linderoth, T. L. Andresen, O. G. Mouritsen, K. Jørgensen, G. Peters, Biophys. J. 2006, 90, 3165-3175;
24. b) S. S. Jensen, T. L. Andresen, J. Davidsen, P. Høyrup, S. D. Shnyder, M. C. Bibby, J. H. Gill, K. Jørgensen, Mol. Cancer Ther. 2004, 3, 1451 -1458.